Novo Holdings invests into AI CRO ExScient...Novo Holdings leads the current US$60m Series C round of ExScientia Ltd, the world-leading artificial intelligence (AI)-driven drug discovery company. more ➔
Poxel SA raises €17.7m through capital i...Metabolic disease specialist Poxel SA has announced a private placement of 2,358,483 new ordinary shares at €0.02 per share reserved to specified investors. more ➔
British scientists start Phase II on COVID...Researchers at the University Oxford and AstraZeneca have started enrolment for a Phase II/III trial to test a COVID-19 vaccine in 10,000 volunteers. more ➔
SARS-CoV2 antibody tests: not suited for i...An international research consortium provides data demonstrating that SARS-CoV-2 antibody tests are only useful for population-based analyses. more ➔
Vaccine to protect from any viral infectio...Two companies have presented a novel vaccination concept that might protect risk groups from new SARS-CoV-2 variants. more ➔
Abivax bags €36m fund for COVID-19 progr...French Abivax SA has received a €36m non-dilutive funding from Bpifrance for its ABX464 Covid-19 programme. more ➔
4Teen4’s DPP3 predicts burn mortalit...4TEEN4 Pharmaceuticals GmbH published data suggesting that high plasma levels of dipeptidyl peptidase 3 were indicative for upcoming multiple organ failure in burn patients. more ➔
IMI ramps up COVID fundThe funding pot of the Innovation Medicines Initiative has been boosted to €117m. IMI has also selected eight projects to fund. more ➔
S-Protein: Glycosylation pattern revealedBritish researchers have deciphered the glycosylation pattern of the viral spike protein of SARS-CoV-2 laying the foundation for vaccine development. more ➔
Newron terminates sarizotan development in...Newron Pharmaceuticals S.p.A.s Sarizotan failed to meet efficacy endpoints in the Phase III STARS study. more ➔
